钠–葡萄糖协同转运蛋白2抑制剂与心力衰竭患者交感神经功能的研究进展
Research Progress on Sodium-Dependent Glucose Transporters 2 Inhibitors and Sym-pathetic Nerve Function in Patients with Heart Failure
摘要: 交感神经(SNS)过度兴奋是导致心力衰竭发生发展的重要机制之一。钠–葡萄糖协同转运蛋白2 (SGLT2)抑制剂是治疗心力衰竭的新型药物，近来研究发现，SGLT2抑制剂可以通过降低心力衰竭患者SNS的功能来使心血管获益。本文着重从SGLT2i对于心力衰竭的获益及机制进行综述，以提高临床工作者在心力衰竭治疗中对SGLT2抑制剂与交感神经关系的认识。
Abstract: Sympathetic nervous system (SNS) hyperexcitation is one of the important mechanisms leading to the development of heart failure. Sodium-dependent glucose transporters 2 (SGLT2) inhibitors are novel drugs for the treatment of heart failure, and recent studies have found that SGLT2 inhibitors can confer cardiovascular benefits by reducing the function of SNS in patients with heart failure. This article focuses on the benefits and mechanisms of SGLT2i in heart failure, so as to improve the understanding of the relationship between SGLT2 inhibitors and sympathetic nerves in the treat-ment of heart failure.
文章引用：李文杰, 刘凯文, 王贵鹏. 钠–葡萄糖协同转运蛋白2抑制剂与心力衰竭患者交感神经功能的研究进展[J]. 临床医学进展, 2024, 14(3): 160-164. https://doi.org/10.12677/ACM.2024.143680

参考文献

[1] Truby, L.K. and Rogers, J.G. (2020) Advanced Heart Failure: Epidemiology, Diagnosis, and Therapeutic Approaches. JACC: Heart Failure, 8, 523-536. [Google Scholar] [CrossRef] [PubMed]
[2] Metra, M. and Lucioli, P. (2020) Corrigendum to ‘Prevalence of Heart Failure and Left Ventricular Dysfunction in China: the China Hypertension Survey, 2012-2015’ [Eur J Heart Fail 2019; 21: 1329-1337]. European Journal of Heart Failure, 22, 759. [Google Scholar] [CrossRef] [PubMed]
[3] 国家心血管病医疗质量控制中心专家委员会心力衰竭专家工作组[J]. 2020中国心力衰竭医疗质量控制报告. 中国循环杂志, 2021, 36(3), 221-238.
[4] Greene, S.J., Bauersachs, J., Brugts, J.J., et al. (2023) Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions: JACC Review Topic of the Week. Journal of the American College of Cardiology, 81, 413-424. [Google Scholar] [CrossRef] [PubMed]
[5] McDonagh, T.A., Metra, M., Adamo, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. [Google Scholar] [CrossRef] [PubMed]
[6] Shugg, T., Hudmon, A. and Overholser, B.R. (2020) Neurohormonal Regulation of I(Ks) in Heart Failure: Implications for Ventricular Arrhythmogenesis and Sudden Cardiac Death. Journal of the American Heart Association, 9, e016900. [Google Scholar] [CrossRef] 
[7] Manolis, A.A., Manolis, T.A. and Manolis, A.S. (2023) Neuro-humoral Activation in Heart Failure. International Journal of Molecular Sciences, 24, Article 15472. [Google Scholar] [CrossRef] [PubMed]
[8] Usman, M.S., Siddiqi, T.J., Anker, S.D., et al. (2023) Effect of SGLT2 Inhibitors on Cardiovascular Outcomes across Various Patient Populations. Journal of the American College of Cardiology, 81, 2377-2387. [Google Scholar] [CrossRef] [PubMed]
[9] McMurray, J., Solomon, S.D., Inzucchi, S.., et al. (2019) Dapagli-flozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 381, 1995-2008. [Google Scholar] [CrossRef] 
[10] Vaduganathan, M., Docherty, K.F., Claggett, B.L., et al. (2022) SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Con-trolled Trials. The Lancet, 400, 757-767. [Google Scholar] [CrossRef] 
[11] Scheen, A.J. (2019) Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Current Cardiology Reports, 21, Article No. 70. [Google Scholar] [CrossRef] [PubMed]
[12] Shimizu, W., Kubota, Y., Hoshika, Y., et al. (2020) Effects of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Di-abetes Mellitus: the EMBODY Trial. Cardiovascular Diabetology, 19, Article No. 148. [Google Scholar] [CrossRef] [PubMed]
[13] Chiba, Y., Sugiyama, Y., Nishi, N., et al. (2020) Sodi-um/Glucose Cotransporter 2 Is Expressed in Choroid Plexus Epithelial Cells and Ependymal Cells in Human and Mouse Brains. Neuropathology, 40, 482-491. [Google Scholar] [CrossRef] [PubMed]
[14] Abbott, N.J., Patabendige, A.A., Dolman, D.E., et al. (2010) Structure and Function of the Blood-Brain Barrier. Neurobiology of Disease, 37, 13-25. [Google Scholar] [CrossRef] [PubMed]
[15] Nguyen, T., Wen, S., Gong, M., et al. (2020) Dapagliflozin Acti-vates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice. Di-abetes, Metabolic Syndrome and Obesity, 13, 2781-2799. [Google Scholar] [CrossRef] 
[16] Amin, E.F., Rifaai, R.A. and Abdel-Latif, R.G. (2020) Empagliflozin Attenuates Transient Cerebral Ischemia/Reperfusion Injury in Hyperglycemic Rats via Repressing Oxidative-Inflammatory-Apoptotic Pathway. Fundamental & Clinical Pharma-cology, 34, 548-558. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, Y., Wen, W. and Liu, H. (2020) the Role of Immune Cells in Cardiac Remodeling after Myocardial Infarction. Journal of Cardiovascular Pharmacology, 76, 407-413. [Google Scholar] [CrossRef] 
[18] Koyani, C.N., Plastira, I., Sourij, H., et al. (2020) Empagliflozin Protects Heart from Inflammation and Energy Depletion via AMPK Activation. Pharmacological Re-search, 158, Article ID: 104870. [Google Scholar] [CrossRef] [PubMed]
[19] Byrne, N.J., Matsumura, N., Maayah, Z.H., et al. (2020) Empagli-flozin Blunts Worsening Cardiac Dysfunction Associated with Reduced NLRP3 (Nucleotide-Binding Domain-Like Re-ceptor Protein 3) Inflammasome Activation in Heart Failure. Circulation: Heart Failure, 13, e006277. [Google Scholar] [CrossRef] 
[20] Kim, S.R., Lee, S.G., Kim, S.H., et al. (2020) SGLT2 Inhibition Modulates NLRP3 Inflammasome Activity via Ketones and Insulin in Diabetes with Cardiovascular Disease. Nature Communications, 11, Article No. 2127. [Google Scholar] [CrossRef] [PubMed]
[21] 孙帅锋, 刘巍. 心肌纤维化病理机制及诊疗策略进展[J]. 国际心血管病杂志, 2020, 47(5), 264-267.
[22] Santos-Gallego, C.G., Requena-Ibanez, J.A., San, A.R., et al. (2021) Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study. JACC: Cardiovascular Imaging, 14, 393-407. [Google Scholar] [CrossRef] [PubMed]
[23] Lee, T.M., Chang, N.C. and Lin, S.Z. (2017) Dapagliflozin, a Se-lective SGLT2 Inhibitor, Attenuated Cardiac Fibrosis by Regulating the Macrophage Polarization via STAT3 Signaling in Infarcted Rat Hearts. Free Radical Biology and Medicine, 104, 298-310. [Google Scholar] [CrossRef] [PubMed]
[24] Tkaczyszyn, M., Górniak, K.M., Lis, W.H., et al. (2022) Iron Deficiency and Deranged Myocardial Energetics in Heart Failure. International Journal of Environmental Research and Public Health, 19, Article 17000. [Google Scholar] [CrossRef] [PubMed]
[25] Santos-Gallego, C.G., Requena-Ibanez, J.A., San, A.R., et al. (2019) Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology, 73, 1931-1944. [Google Scholar] [CrossRef] [PubMed]
[26] Oh, C.M., Cho, S., Jang, J.Y., et al. (2019) Cardioprotective Poten-tial of an SGLT2 Inhibitor against Doxorubicin-Induced Heart Failure. Korean Circulation Journal, 49, 1183-1195. [Google Scholar] [CrossRef] [PubMed]

为你推荐